All News

10 November 2008

Ophthotech Treats First Patient in a Phase I Trial of Monoclonal Antibody, Volociximab, for Age-Related Macular DegenerationAntibodies

7 November 2008

InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private PlacementAntibodies

4 November 2008

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer CellsAntibodies

4 November 2008

YM Biosciences Reports Data From Exploratory Clinical Trials of Nimotuzumab in Brain Metastases and High-Grade Glioma Presentes at 2008 EORTC-NCI-AACR Annual MeetingAntibodies

3 November 2008

Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain CancerAntibodies

3 November 2008

CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic MelanomaAntibodies

3 November 2008

Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)Antibodies

1 November 2008

GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical TrialAntibodies

30 October 2008

Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 MoleculeAntibodies

30 October 2008

ERBITUX(R) Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug AdministrationAntibodies

30 October 2008

New Cimzia(R) study shows rapid reduction of symptoms and progression of rheumatoid arthritisAntibodies

29 October 2008

Merck KGaA and Lpath Form Alliance for ASONEPAntibodies

29 October 2008

Phase 2a Data for MEDI-528 Presented at CHEST 2008Antibodies

28 October 2008

Affitech Acquires Pharmexa’s Diabody TechnologyAntibodies

28 October 2008

Seattle Genetics Presents on SGN-70 at American College of Rheumatology MeetingAntibodies

28 October 2008

BioWa Announces License of Biowa’s Potelligent(R) Technology to KaloBios PharmaceuticalsAntibodies

28 October 2008

Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)Antibodies

28 October 2008

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With LupusAntibodies

27 October 2008

Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic ArthritisAntibodies

27 October 2008

ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseasesAntibodies

27 October 2008

New Study Shows ENBREL(R) (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis PatientsAntibodies

27 October 2008

WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSLAntibodies

27 October 2008

Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid ArthritisAntibodies

27 October 2008

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two YearsAntibodies

27 October 2008

Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms of Novel HIV Therapy PRO 140Antibodies

27 October 2008

Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid ArthritisAntibodies

27 October 2008

New data shows ACTEMRA inhibits progression of joint destruction and improves physical function of patients with Rheumatoid ArthritisAntibodies

27 October 2008

One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 StudyAntibodies

25 October 2008

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis PatientsAntibodies

24 October 2008

Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate ProgramsAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Mesothelin-Targeted Immunotherapy Pipeline Review

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Adalimumab (Humira) Biosimilars Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

TL1A Inhibitor Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

B7-H4 Targeted Antibody Therapy Pipeline Review